Xeris Biopharma Holdings, Inc. - Laporan Laba Rugi (TTM)

Xeris Biopharma Holdings, Inc.
GB ˙ LSE ˙ US98422E1038
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Xeris Biopharma Holdings, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 15 20 27 34 35 50 63 80 99 110 121 134 153 164 171 181 187 203 223 246
Change (%) 35.09 31.35 25.63 4.78 40.35 27.99 25.84 23.37 11.89 10.09 10.47 13.87 7.37 4.54 5.87 3.28 8.38 9.59 10.55
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 8 9 9 11 12 13 18 19 21 23 22 24 27 29 29 30 35 37 40 44
Change (%) 23.98 0.39 22.26 3.39 12.52 33.39 8.03 10.63 6.60 -4.21 12.66 12.04 4.67 2.28 0.80 18.26 5.46 7.49 10.38
% of Revenue 49.74 45.65 34.89 33.95 33.50 26.86 27.99 24.03 21.55 20.53 17.86 18.22 17.93 17.48 17.10 16.28 18.64 18.14 17.79 17.76
Gross Operating Profit 8 11 17 22 23 36 46 61 77 88 100 110 125 135 142 152 152 166 183 202
Change (%) 46.09 57.36 27.43 5.50 54.37 26.00 32.76 27.40 13.34 13.78 9.99 14.28 7.95 5.02 6.91 0.37 9.05 10.06 10.58
% of Revenue 50.26 54.35 65.11 66.05 66.50 73.14 72.01 75.97 78.45 79.47 82.14 81.78 82.07 82.52 82.90 83.72 81.36 81.86 82.21 82.24
SG&A 76 74 71 79 90 116 143 150 158 138 134 139 141 146 151 153 161 157 163 167
Change (%) -3.46 -3.43 11.63 12.64 29.62 22.83 4.95 5.32 -12.58 -2.76 3.47 2.02 3.32 3.27 1.56 5.01 -2.19 3.58 2.70
% of Revenue 504.90 360.81 265.27 235.72 253.41 234.04 224.61 187.32 159.91 124.94 110.36 103.38 92.62 89.13 88.04 84.46 85.88 77.50 73.25 68.05
R&D 28 19 16 16 18 25 27 26 26 21 20 22 21 22 25 25 26 26 25 28
Change (%) -32.98 -13.82 0.58 10.90 38.33 8.82 -6.08 1.48 -19.65 -6.73 12.12 -4.60 6.82 13.35 -1.30 3.42 -1.12 -0.27 9.01
% of Revenue 186.63 92.59 60.75 48.64 51.48 50.74 43.14 32.19 26.48 19.02 16.11 16.35 13.70 13.63 14.78 13.78 13.80 12.59 11.45 11.29
OpEx 112 102 97 107 120 155 191 200 214 192 186 196 201 208 216 219 233 231 239 250
Change (%) -9.05 -5.01 10.80 11.39 29.72 23.13 4.99 6.53 -10.01 -3.21 5.25 2.41 3.69 4.04 1.05 6.37 -0.82 3.61 4.52
% of Revenue 741.26 499.05 360.90 318.30 338.38 312.74 300.87 251.02 216.75 174.32 153.27 146.03 131.34 126.85 126.25 120.50 124.11 113.56 107.37 101.51
Operating Income -97 -82 -70 -74 -84 -105 -127 -121 -115 -82 -65 -62 -48 -44 -45 -37 -45 -28 -16 -4
Change (%) -15.94 -14.12 5.11 14.42 25.25 20.84 -5.39 -4.62 -28.77 -21.09 -4.54 -22.47 -8.03 2.20 -17.32 21.46 -39.01 -40.50 -77.29
% of Revenue -641.26 -399.05 -260.90 -218.30 -238.38 -212.74 -200.87 -151.02 -116.75 -74.32 -53.27 -46.03 -31.34 -26.85 -26.25 -20.50 -24.11 -13.56 -7.37 -1.51
Interest Expense -8 -11 -11 -11 -10 -7 -9 -11 -12 -14 -17 -20 -24 -27 -27 -29 -30 -30 -31 -30
Change (%) 40.26 2.74 -4.08 -5.05 -28.02 24.09 18.55 9.16 22.30 19.11 18.34 20.53 11.07 3.07 5.24 3.25 2.30 0.90 -1.97
% of Revenue -50.24 -52.17 -40.80 -31.15 -28.23 -14.48 -14.04 -13.23 -11.70 -12.79 -13.84 -14.83 -15.69 -16.23 -16.00 -15.91 -15.91 -15.01 -13.82 -12.26
Net Income -102 -91 -80 -84 -94 -123 -138 -137 -133 -95 -78 -71 -62 -62 -64 -60 -63 -55 -45 -32
Change (%) -10.97 -11.82 4.25 11.95 30.85 12.47 -0.96 -3.06 -28.57 -17.83 -8.16 -13.50 0.74 3.45 -7.51 5.96 -13.11 -17.80 -29.01
% of Revenue -676.70 -446.00 -299.41 -248.46 -265.45 -247.48 -217.48 -171.15 -134.49 -85.86 -64.08 -53.28 -40.48 -37.98 -37.58 -32.83 -33.69 -27.00 -20.25 -13.01

Source: Capital IQ

Other Listings
DE:2B30 € 6.64
US:XERS US$ 7.85
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista